{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T05:27:01Z","timestamp":1731475621986,"version":"3.28.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,12]]},"DOI":"10.7759\/cureus.73525","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T14:03:12Z","timestamp":1731420192000},"source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant Chemotherapy vs Chemoradiotherapy for Malignancy of Esophagus: A Prospective Comparative Study"],"prefix":"10.7759","author":[{"given":"Vaibhav K","family":"Varshney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishu","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Selvakumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subhash","family":"Soni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peeyush","family":"Varshney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lokesh","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunita","family":"Suman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bharti","family":"Varshney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabir","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akhil Dhanesh","family":"Goel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Puneet","family":"Pareek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Poonam","family":"Elhence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial","volume":"16","author":"Shapiro J","year":"2015","unstructured":"Shapiro J, van Lanschot JJ, Hulshof MC, et al.. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015, 16:1090-8. 10.1016\/S1470-2045(15)00040-6","journal-title":"Lancet Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.04.027","article-title":"Preoperative chemotherapy versus chemoradiotherapy in\u00a0locally advanced adenocarcinomas of the oesophagogastric junction (POET): long-term results of\u00a0a controlled randomised trial","volume":"81","author":"Stahl M","year":"2017","unstructured":"Stahl M, Walz MK, Riera-Knorrenschild J, et al.. Preoperative chemotherapy versus chemoradiotherapy in\u00a0locally advanced adenocarcinomas of the oesophagogastric junction (POET): long-term results of\u00a0a controlled randomised trial. Eur J Cancer. 2017, 81:183-90. 10.1016\/j.ejca.2017.04.027","journal-title":"Eur J Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2010.04.061","article-title":"Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer","volume":"90","author":"Swisher SG","year":"2010","unstructured":"Swisher SG, Hofstetter W, Komaki R, et al.. Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. Ann Thorac Surg. 2010, 90:892-8; discussion 898-9. 10.1016\/j.athoracsur.2010.04.061","journal-title":"Ann Thorac Surg"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.09.009","article-title":"Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial","volume":"47","author":"Burmeister BH","year":"2011","unstructured":"Burmeister BH, Thomas JM, Burmeister EA, et al.. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer. 2011, 47:354-60. 10.1016\/j.ejca.2010.09.009","journal-title":"Eur J Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2007.11.070","article-title":"Neoadjuvant chemoradiation versus chemotherapy for patients undergoing esophagectomy for esophageal cancer","volume":"85","author":"Luu TD","year":"2008","unstructured":"Luu TD, Gaur P, Force SD, Staley CA, Mansour KA, Miller JI Jr, Miller DL. Neoadjuvant chemoradiation versus chemotherapy for patients undergoing esophagectomy for esophageal cancer. Ann Thorac Surg. 2008, 85:1217-24. 10.1016\/j.athoracsur.2007.11.070","journal-title":"Ann Thorac Surg"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.5671","article-title":"Prospective cohort comparison of neoadjuvant chemoradiotherapy versus chemotherapy in patients with oesophageal cancer","volume":"94","author":"Morgan MA","year":"2007","unstructured":"Morgan MA, Lewis WG, Crosby TD, et al.. Prospective cohort comparison of neoadjuvant chemoradiotherapy versus chemotherapy in patients with oesophageal cancer. Br J Surg. 2007, 94:1509-14. 10.1002\/bjs.5671","journal-title":"Br J Surg"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30531-9","article-title":"Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2\/3 trial","volume":"17","author":"Al-Batran SE","year":"2016","unstructured":"Al-Batran SE, Hofheinz RD, Pauligk C, et al.. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2\/3 trial. Lancet Oncol. 2016, 17:1697-708. 10.1016\/S1470-2045(16)30531-9","journal-title":"Lancet Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham D","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, et al.. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006, 355:11-20. 10.1056\/NEJMoa055531","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5223(03)00710-4","article-title":"Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial","volume":"126","author":"Keresztes RS","year":"2003","unstructured":"Keresztes RS, Port JL, Pasmantier MW, Korst RJ, Altorki NK. Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial. J Thorac Cardiovasc Surg. 2003, 126:1603-8. 10.1016\/s0022-5223(03)00710-4","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2015.03.226","article-title":"Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: a randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation","volume":"41","author":"Klevebro F","year":"2015","unstructured":"Klevebro F, Johnsen G, Johnson E, et al.. Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: a randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation. Eur J Surg Oncol. 2015, 41:920-6. 10.1016\/j.ejso.2015.03.226","journal-title":"Eur J Surg Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez A","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed). 2021, 112:90-2. 10.1016\/j.ad.2019.05.009","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3181b13ca2","article-title":"The Clavien-Dindo classification of surgical complications: five-year experience","volume":"250","author":"Clavien PA","year":"2009","unstructured":"Clavien PA, Barkun J, de Oliveira ML, et al.. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009, 250:187-96. 10.1097\/SLA.0b013e3181b13ca2","journal-title":"Ann Surg"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2005.02176.x","article-title":"Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer","volume":"47","author":"Ryan R","year":"2005","unstructured":"Ryan R, Gibbons D, Hyland JM, et al.. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 2005, 47:141-6. 10.1111\/j.1365-2559.2005.02176.x","journal-title":"Histopathology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0033","article-title":"Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Ajani JA","year":"2019","unstructured":"Ajani JA, D'Amico TA, Bentrem DJ, et al.. Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019, 17:855-83. 10.6004\/jnccn.2019.0033","journal-title":"J Natl Compr Canc Netw"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00243-1","article-title":"Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial","volume":"8","author":"Reynolds JV","year":"2023","unstructured":"Reynolds JV, Preston SR, O'Neill B, et al.. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial. Lancet Gastroenterol Hepatol. 2023, 8:1015-27. 10.1016\/S2468-1253(23)00243-1","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-011-2049-9","article-title":"A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907)","volume":"19","author":"Ando N","year":"2012","unstructured":"Ando N, Kato H, Igaki H, et al.. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012, 19:68-74. 10.1245\/s10434-011-2049-9","journal-title":"Ann Surg Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00745-1","article-title":"Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial","volume":"6","author":"Kato K","year":"2024","unstructured":"Kato K, Machida R, Ito Y, et al.. Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial. Lancet. 2024, 6:55-66. 10.1016\/S0140-6736(24)00745-1","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.10.508","article-title":"Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial","volume":"34","author":"Tang H","year":"2023","unstructured":"Tang H, Wang H, Fang Y, et al.. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial. Ann Oncol. 2023, 34:163-72.","journal-title":"Ann Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.11246","article-title":"Health-related quality of life in a randomized trial of neoadjuvant chemotherapy or chemoradiotherapy plus surgery in patients with oesophageal cancer (NeoRes trial)","volume":"106","author":"Sunde B","year":"2019","unstructured":"Sunde B, Klevebro F, Johar A, et al.. Health-related quality of life in a randomized trial of neoadjuvant chemotherapy or chemoradiotherapy plus surgery in patients with oesophageal cancer (NeoRes trial). Br J Surg. 2019, 106:1452-63. 10.1002\/bjs.11246","journal-title":"Br J Surg"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0271242","article-title":"Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for esophageal squamous cell cancer: a meta-analysis","volume":"17","author":"Guo Y","year":"2022","unstructured":"Guo Y, Xu M, Lou Y, et al.. Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for esophageal squamous cell cancer: a meta-analysis. PLoS One. 2022, 17:e0271242. 10.1371\/journal.pone.0271242","journal-title":"PLoS One"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.4103\/jmas.jmas_303_22","article-title":"Short-term outcomes of enhanced recovery after surgery protocol in minimally invasive oesophagectomy: a prospective study","volume":"20","author":"Sreesanth KS","year":"2024","unstructured":"Sreesanth KS, Soni SC, Varshney VK, Puranik AK, Bhatia PK. Short-term outcomes of enhanced recovery after surgery protocol in minimally invasive oesophagectomy: a prospective study. J Minim Access Surg. 2024, 20:196-200. 10.4103\/jmas.jmas_303_22","journal-title":"J Minim Access Surg"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-022-05341-w","article-title":"Intra-nodal indocyanine green injection to delineate thoracic duct during minimally invasive esophagectomy","volume":"26","author":"Varshney VK","year":"2022","unstructured":"Varshney VK, Nayar R, Soni SC, Selvakumar B, Garg PK, Varshney P, Khera PS. Intra-nodal indocyanine green injection to delineate thoracic duct during minimally invasive esophagectomy. J Gastrointest Surg. 2022, 26:1559-65. 10.1007\/s11605-022-05341-w","journal-title":"J Gastrointest Surg"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2018.11.052","article-title":"Radiation with neoadjuvant chemotherapy does not improve outcomes in esophageal squamous cell cancer","volume":"236","author":"Miller JA","year":"2019","unstructured":"Miller JA, Groman A, Yendamuri S, Hennon M. Radiation with neoadjuvant chemotherapy does not improve outcomes in esophageal squamous cell cancer. J Surg Res. 2019, 236:259-65. 10.1016\/j.jss.2018.11.052","journal-title":"J Surg Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly RJ","year":"2021","unstructured":"Kelly RJ, Ajani JA, Kuzdzal J, et al.. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021, 384:1191-203. 10.1056\/NEJMoa2032125","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0189","article-title":"Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E)","volume":"16","author":"Yamamoto S","year":"2020","unstructured":"Yamamoto S, Kato K, Daiko H, et al.. Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E). Future Oncol. 2020, 16:1351-7. 10.2217\/fon-2020-0189","journal-title":"Future Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/315909-neoadjuvant-chemotherapy-vs-chemoradiotherapy-for-malignancy-of-esophagus-a-prospective-comparative-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T14:03:14Z","timestamp":1731420194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/315909-neoadjuvant-chemotherapy-vs-chemoradiotherapy-for-malignancy-of-esophagus-a-prospective-comparative-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,12]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.73525","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,12]]}}}